Citations

Clear

431 citation(s) found for "Schmidt, C".

Abstract 5240: Functional and therapeutic significance of ESR1 gene fusions in breast cancer
Shao, Jieya , Iglesia, Michael D. , Chan, Doug W. , Jin, Cao , Singh, Purba , He, Xiaping , Kosaka, Yoshimasa , Matsunuma, Ryoichi , Crowder, Robert J., Phommaly, Chanpheng, Gonçalves, Rodrigo , Romalho, Susana, Peres, Raquel Mary Rodrigues , Punturi, Nindo , Schmidt, Cheryl, Bartram, Alex, Jou, Eric , Lai, W V., Rogers, Anna , Tobias, Ethan, Parikh, Poojan A., Li, Shunqiang , Cynthia, X. , Thompson, Emily A. , Kavuri, Shyam M. , Creighton, Chad J. , Maher, Christopher A. , Haricharan, Svasti , Lei, Jonathan T. , Zhang, Jin , Anurag, Meenakshi , Hoog, Jeremy , Lai, W V., Hampton, Oliver , Davies, Sherri R. , Suman, Vera J. , Hunt, Kelly K. , Watson, Mark A. , Hoadley, Katherine A. , Thompson, E A., Chen, Xi , Perou, Charles M. , Ellis, Matthew J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5240-5240

10.1158/1538-7445.am2018-5240 Get It

Abstract RNA sequencing detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. Herein we examined multiple in-frame and out-of-frame ESR1 fusions and found only two, both identified in advanced endocrine treatment resistant disease, encoded stable and functional in-frame fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, the N-terminal, DNA binding and dimerization motifs encoded by exons 2-6 were fused to C-terminal sequences from the partner gene. Functional properties included estrogen-independent growth, constitutive expression of ER target genes, anti-estrogen resistance, induction of cellular motility in vitro and the development of lung metastasis in vivo. Chromatin immunoprecipitation and RNA sequencing experiments showed both fusions uniquely activated a metastasis-associated transcriptional program. ESR1-e6>YAP1 and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, palbociclib, and a patient-derived xenograft (PDX) expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective. Citation Format: Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Romalho, Raquel M. Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, W V. Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E A. Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, Matthew J. Ellis. Functional and therapeutic significance of ESR1 gene fusions in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5240.
Abstract 2211: Patient level polygenic risk scores and continuous estrogen receptor expression in breast cancer
Shetty, Anamay , Blows, Fiona M., Inard, Nicholas, Couch, Fergus J., Easton, Douglas F. , Mannermaa, Arto, Raza, Ali , Caldas, Carlos , Benı́tez, Javier , Chang, Jenny C. , Chenevix‐Trench, Georgia , Couch, Fergus J. , Cox, Angela , Devilee, Peter , García‐Closas, Montserrat , Mannermaa, Arto, Nevanlinna, Heli , Schmidt, Marjanka K. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 2211-2211

10.1158/1538-7445.am2018-2211 Get It

Abstract Introduction: Genome-wide association studies over the past 10 years have identified over 100 common variants associated with breast cancer risk. The association of these polymorphisms varies according to estrogen receptor status of the tumor, with some associated primarily with ER+ or ER- disease, or both subtypes. However, ER expression in breast cancer cells is continuous. The aim of this study was to establish whether the association between polygenic risk scores and ER expression in breast cancer is continuous in nature. Methods: Data were taken from the international Breast Cancer Association Consortium (BCAC). Germline genotype data for 75 SNPs previously reported to be associated with breast cancer were available for 4,999 breast cancer cases for which ER expression data were also available. Automated ER expression on a continuous scale was measured using two image analysis algorithms: Astrogrid and Ariol. A third form of ER expression score, the manual Allred ordinal, was used. Genotype data were used to calculate polygenic risk scores using the equation: PRS = ∑ βx where β is the log-odds of the odds ratio (OR) of breast cancer associated with that single nucleotide polymorphism (SNP), and x is the number of variant alleles at a SNP locus. Five different PRSs were calculated: i) SNPs associated with both ER+ and ER- disease (PRS-A, n= 74) ii) SNPs associated with ER+ disease at P<0.01 (PRS-B, n= 65) iii) SNPs associated with ER- disease at P<0.01 (PRS-C, n= 43) iv) SNPs associated with ER+ but not ER- disease (PRS-D, n= 30) v) SNPs associated with ER- but not ER+ disease (PRS-E, n = 8) The ER-specific weights for the PRS were taken from previous OR estimates. Linear regression models adjusted for study were used to test for a relationship between the five PRSs and ER expression measured on the Ariol, Astrogrid and Allred scales. Results: There was a strong positive correlation found between PRS-B against Astrogrid (β=0.0176, P=4.06x10-4), a weak negative correlation found with PRS-C (β=-0.012, P=0.019) and a weak positive correlation for PRS-A (β=0.012, P=0.0144). PRS-D and E showed far stronger association with Astrogrid than PRS-B and C, respectively (β=0.0186 and -0.017, P=1.97x10-4 and 8.1x10-4). There was a qualitatively similar association when the PRSs were correlated with Ariol and Allred, apart from the stronger correlations with PRS-B (β=91.2 and 0.0853, P=5.52x10-4 and 1.33x10-3). Conclusion: We have shown a robust association between PRS and ER expression in the directions we predicted. This suggests that the continuous variation in ER expression is biologically plausible and linked to genetic polymorphism. The weakening of association with PRS-A and the stronger associations with PRS-D and E show that having SNPs that are associated with both ER subtypes in the same PRS weakens significance, and suggests that subtype-specific PRSs may be improved on by using SNPs exclusive to the respective subtype. Citation Format: Anamay H. Shetty, Raza Ali, Fiona Blows, Carlos Caldas, Nicholas Inard, Javier Benítez, Jenny Chang-Claude, Georgia Chenevix-Trench, Fergus Couch, Angela Cox, Peter Devilee, Douglas Easton, Montserrat Garcia-Closas, Arto Mannermaa, Heli Nevanlinna, Marjanka Schmidt, Paul Pharoah. Patient level polygenic risk scores and continuous estrogen receptor expression in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2211.
Exome Chip Analysis Identifies Low-Frequency and Rare Variants in MRPL38 for White Matter Hyperintensities on Brain Magnetic Resonance Imaging
Jian, Xueqiu , Satizábal, Claudia L. , Smith, Albert V. , Wittfeld, Katharina , Bis, Joshua C. , Smith, Jennifer A. , Hofer, Edith , Mishra, Aniket , Adams, Hieab H.H. , Li, Shuo , Teumer, Alexander , Zhao, Wei , Saba, Yasaman , Yanek, Lisa R. , Chauhan, Ganesh , Buchem, Mark A. van , Royle, Natalie A., Niessen, Wiro J. , Windham, B. Gwen , DeStefano, Anita L. , Habes, Mohamad , Heckbert, Susan R. , Palmer, Nicholette D., Lewis, Cora E. , Eiríksdóttir, Guðný , Maillard, Pauline , Mathias, Rasika A. , Divers, Jasmin, Beiser, Alexa S., Langner, Sönke , Rice, Kenneth , Bastin, Mark E. , Starr, John M. , Sidney, Stephen , Risacher, Shannon L. , Uitterlinden, André G. , Guðnason, Vilmundur , Rotter, Jerome I. , Schreiner, Pamela J. , Boerwinkle, Eric , Duijn, Cornelia M. van , Sarnowski, Bettina von , Gottesman, Rebecca F., Levy, Daniel , Sigurðsson, Sigurður , Vernooij, Meike W. , Schmidt, Reinhold, Wardlaw, Joanna M. , Mosley, Thomas H. , DeCarli, Charles , Bowden, Donald W. , Becker, Diane M. , Deary, Ian J. , Schmidt, Helena , Kardia, Sharon L. R., Debette, Stéphanie , Longstreth, W.T. , Seshadri, Sudha , Launer, Lenore J. , Fornage, Myriam , Group, for the neuroCHARGE Working, Dichgans, Martin , Rice, Kenneth , Palmer, Nicholette D. , DeCarli, Charles , Turner, Stephen T. , Dichgans, Martin , Wardlaw, Joanna Marguerite , Smith, Jennifer A , Adams, Hieab H H , Satizabal, Claudia L , Seshadri, Sudha , Bastin, Mark E , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Smith, Albert V , Palmer, Nicholette D , Rotter, Jerome I , Mathias, Rasika A , Rice, Ken , Levy, Daniel , Hsu, Fang‐Chi , Nho, Kwangsik T. , Hagenaars, Saskia P. , Nyquist, Paul , Freedman, Barry I. , Cushman, Mary , Bryan, Robert Nick , Homuth, Georg , Hernández, Maria del Carmen Valdés , Divers, Jasmin , Yang, Qiong , Maldjian, Joseph A. , Nauck, Matthias A. , Mazoyer, Bernard , Psaty, Bruce M. , Saykin, Andrew J. , Ikram, M. Arfan , Grabe, Hans Jörgen , Group, for the neuroCHARGE Working, Maillard, Pauline

Mayo Clinic

Stroke | July 12, 2018 | Volume: 49 | Issue: 8 | Pages: 1812-1819

10.1161/strokeaha.118.020689 | PMID 30002152 Get It

Background and Purpose— White matter hyperintensities (WMH) on brain magnetic resonance imaging are typical signs of cerebral small vessel disease and may indicate various preclinical, age-related neurological disorders, such as stroke. Though WMH are highly heritable, known common variants explain a small proportion of the WMH variance. The contribution of low-frequency/rare coding variants to WMH burden has not been explored. Methods— In the discovery sample we recruited 20 719 stroke/dementia-free adults from 13 population-based cohort studies within the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, among which 17 790 were of European ancestry and 2929 of African ancestry. We genotyped these participants at ≈250 000 mostly exonic variants with Illumina HumanExome BeadChip arrays. We performed ethnicity-specific linear regression on rank-normalized WMH in each study separately, which were then combined in meta-analyses to test for association with single variants and genes aggregating the effects of putatively functional low-frequency/rare variants. We then sought replication of the top findings in 1192 adults (European ancestry) with whole exome/genome sequencing data from 2 independent studies. Results— At 17q25, we confirmed the association of multiple common variants in TRIM65 , FBF1 , and ACOX1 ( P <6×10 −7 ). We also identified a novel association with 2 low-frequency nonsynonymous variants in MRPL38 (lead, rs34136221; P EA =4.5×10 −8 ) partially independent of known common signal ( P EA(conditional) =1.4×10 −3 ). We further identified a locus at 2q33 containing common variants in NBEAL1 , CARF , and WDR12 (lead, rs2351524; P all =1.9×10 −10 ). Although our novel findings were not replicated because of limited power and possible differences in study design, meta-analysis of the discovery and replication samples yielded stronger association for the 2 low-frequency MRPL38 variants ( P rs34136221 =2.8×10 −8 ). Conclusions— Both common and low-frequency/rare functional variants influence WMH. Larger replication and experimental follow-up are essential to confirm our findings and uncover the biological causal mechanisms of age-related WMH.
Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study
Kálmán, János , Papiol, Sergi , Forstner, Andreas J. , Heilbronner, Urs , Degenhardt, Franziska , Adli, Mazda , Adorjan, Kristina , Akula, Nirmala , Alda, Martin , Anderson‐Schmidt, Heike , Andlauer, Till F. M. , Anghelescu, Ion‐George , Ardau, Raffaella , Arias, Bárbara , Arolt, Volker , Aubry, Jean‐Michel , Bartholdi, Kim, Bauer, Michael , Benabarre, Antonio , Bengesser, Susanne , Bhattacharjee, Abesh Kumar, Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Comes, Ashley L. , Cruceanu, Cristiana , Czerski, Piotr M. , Zompo, Maria Del , Dietrich, Detlef E. , Étain, Bruno , Ethofer, Thomas , Falkai, Peter , Fallgatter, Andreas J. , Figge, Christian, Flatau, Laura , Folkerts, Here, Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gade, Katrin , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Gryaznova, Anna, Hake, Maria, Jäger, Markus , Jamain, Stéphane , Jiménez, Esther , Juckel, Georg , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Klohn‐Sagatholislam, Farah, Köller, Manfred , Konrad, Carsten , Lackner, Nina , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Maj, Mario , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , McMahon, Francis J. , Mitjans, Marina , Mondimore, Francis M. , Nieratschker, Vanessa , Novák, Tomáš , Ösby, Urban, Potash, James B. , Reich‐Erkelenz, Daniela , Reif, Andreas , Reimer, Jens , Reininghaus, Eva Z. , Reitt, Markus , Ripke, Stephan , Schalling, Martin , Scherk, Harald, Schmauß, Max, Schubert, Klaus Oliver , Schulte, Eva C. , Schulz, Sybille, Senner, Fanny , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stegmaier, Sophia, Stierl, Sebastian, Stopková, Pavla , Thiel, Andreas , Tighe, Sarah K., Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Veeh, Julia, Hagen, Martin von, Wigand, Moritz E. , Wiltfang, Jens , Zandi, Peter P. , Zimmermann, Jörg , Heilbronner, Maria , Etain, B , Vieta, E , Cichon, Sven , Alda, Martin , Ripke, Stephan , Fullerton, Janice M , Strohmaier, Jana , Aubry, Jean‐Michel , Backlund, Lena , Baune, Bernhard , Becker, Thomas M , Bellivier, Frank , Biernacka, Joanna M. , Budde, Monika , Colom, Francesc , Dannlowski, Udo , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Gryaznova, Anna, Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hou, Liping , Kelsoe, John R , Klöhn-Sagatholislam, Farahnaz, König, Barbara , Lang, Fabian U. , McElroy, Susan L. , Mitchell, Philip B , Monteleone, Palmiero , Nievergelt, Caroline M , Pfennig, Andrea , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Schofield, Peter R. , Spitzer, Carsten , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Nöthen, Markus M. , Rietschel, Marcella , Schulze, Thomas , Papiol, Sergi , Heilbronner, Urs , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kalman, Janos , Schulte, Eva , Wiltfang, Jens , Andlauer, Till , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Schubert, Klaus Oliver , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

Bipolar Disorders | June 28, 2018 | Volume: 21 | Issue: 1 | Pages: 68-75

10.1111/bdi.12659 | PMID 29956436 Get It

Objectives Bipolar disorder (BD) with early disease onset is associated with an unfavorable clinical outcome and constitutes a clinically and biologically homogenous subgroup within the heterogeneous BD spectrum. Previous studies have found an accumulation of early age at onset (AAO) in BD families and have therefore hypothesized that there is a larger genetic contribution to the early‐onset cases than to late onset BD. To investigate the genetic background of this subphenotype, we evaluated whether an increased polygenic burden of BD‐ and schizophrenia (SCZ)‐associated risk variants is associated with an earlier AAO in BD patients. Methods A total of 1995 BD type 1 patients from the Consortium of Lithium Genetics (ConLiGen), PsyCourse and Bonn‐Mannheim samples were genotyped and their BD and SCZ polygenic risk scores (PRSs) were calculated using the summary statistics of the Psychiatric Genomics Consortium as a training data set. AAO was either separated into onset groups of clinical interest (childhood and adolescence [≤18 years] vs adulthood [>18 years]) or considered as a continuous measure. The associations between BD‐ and SCZ‐PRSs and AAO were evaluated with regression models. Results BD‐ and SCZ‐PRSs were not significantly associated with age at disease onset. Results remained the same when analyses were stratified by site of recruitment. Conclusions The current study is the largest conducted so far to investigate the association between the cumulative BD and SCZ polygenic risk and AAO in BD patients. The reported negative results suggest that such a polygenic influence, if there is any, is not large, and highlight the importance of conducting further, larger scale studies to obtain more information on the genetic architecture of this clinically relevant phenotype.
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal Z OTRIP Randomized, Controlled Trial
Tepper, Stewart J. , Friedman, Deborah I. , Gelfand, Amy A. , Kellerman, Donald , Schmidt, Peter , Dodick, David W. , Friedman, Deborah I , Gelfand, Amy A

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 21, 2018 | Volume: 58 | Issue: 7 | Pages: 986-992

10.1111/head.13327 | PMID 29782049 Get It

Objective To better understand the utility of using pain freedom and most bothersome headache‐associated symptom (MBS) freedom as co‐primary endpoints in clinical trials of acute migraine interventions. Background Adhesive dermally applied microarray (ADAM) is an investigational system for intracutaneous drug administration. The recently completed pivotal Phase 2b/3 study (ZOTRIP), evaluating ADAM zolmitriptan for the treatment of acute moderate to severe migraine, was one of the first large studies to incorporate MBS freedom and pain freedom as co‐primary endpoints per recently issued guidance by the US Food and Drug Administration. In this trial, the proportion of patients treated with ADAM zolmitriptan 3.8 mg, who were pain‐free and MBS‐free at 2 hours post‐dose, was significantly higher than for placebo. Methods We undertook a post‐hoc analysis of data from the ZOTRIP trial to examine how the outcomes from this trial compare to what might have been achieved using the conventional co‐primary endpoints of pain relief, nausea, photophobia, and phonophobia. Results Of the 159 patients treated with ADAM zolmitriptan 3.8 mg or placebo, prospectively designated MBS were photophobia (n = 79), phonophobia (n = 43), and nausea (n = 37). Two‐hour pain free rates in those with photophobia as the MBS were 36% for ADAM zolmitriptan 3.8 mg and 14% for placebo ( P = .02). Corresponding rates for those with phonophobia as the MBS were 14% and 41% ( P = .05). For those whose MBS was nausea, corresponding values were 56% and 16%, respectively ( P = .01). Two‐hour freedom from the MBS for active drug vs placebo were 67% vs 35% ( P < .01) for photophobia, 55% vs 43% ( P = .45) for phonophobia, and 89% vs 58% for nausea ( P = .04). MBS freedom but not pain freedom was achieved in 28%. Only 1 patient (1%) achieved pain freedom, but not MBS freedom. The proportion with both pain and MBS freedom was highest (56%) among those whose MBS was nausea. Conclusion In this study, the use of MBS was feasible and seemed to compare favorably to the previously required 4 co‐primary endpoints.
Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Chrysidis, Stavros , Duftner, Christina , Dejaco, Christian , Schäfer, Valentin Sebastian , Carrara, Greta , Scirè, Carlo Alberto , Hočevar, Alojzija , Diamantopoulos, Andreas P. , Iagnocco, Annamaria , Mukhtyar, Chetan , Ponte, Cristina , Naredo, Esperanza , Bruyn, George A. W. , Warrington, Kenneth J. , Terslev, Lene , Milchert, Marcin , D’Agostino, Maria Antonietta , Koster, Mattew J, Rastalsky, Naina, Hánová, Petra , Macchioni, Pierluigi , Kermani, Tanaz A. , Lorenzen, Tove , Døhn, Uffe Møller , Fredberg, Ulrich , Hartung, Wolfgang , Schmidt, Wolfgang , Scirè, Carlo Alberto , Milchert, Marcin , D'Agostino, Maria Antonietta , Dejaco, Christian , Warrington, Kenneth J , Ramiro, Sofía , Miguel, Eugenio de , Koster, Mattew J, Dasgupta, Bhaskar

Mayo Clinic

RMD Open | May 18, 2018 | Volume: 4 | Issue: 1 | Pages: e000598

10.1136/rmdopen-2017-000598 | PMID 29862043 Get It

Objectives To define the elementary ultrasound (US) lesions in giant cell arteritis (GCA) and to evaluate the reliability of the assessment of US lesions according to these definitions in a web-based reliability exercise. Methods Potential definitions of normal and abnormal US findings of temporal and extracranial large arteries were retrieved by a systematic literature review. As a subsequent step, a structured Delphi exercise was conducted involving an expert panel of the Outcome Measures in Rheumatology (OMERACT) US Large Vessel Vasculitis Group to agree definitions of normal US appearance and key elementary US lesions of vasculitis of temporal and extracranial large arteries. The reliability of these definitions on normal and abnormal blood vessels was tested on 150 still images and videos in a web-based reliability exercise. Results Twenty-four experts participated in both Delphi rounds. From originally 25 statements, nine definitions were obtained for normal appearance, vasculitis and arteriosclerosis of cranial and extracranial vessels. The ‘halo’ and ‘compression’ signs were the key US lesions in GCA. The reliability of the definitions for normal temporal and axillary arteries, the ‘halo’ sign and the ‘compression’ sign was excellent with inter-rater agreements of 91–99% and mean kappa values of 0.83–0.98 for both inter-rater and intra-rater reliabilities of all 25 experts. Conclusions The ‘halo’ and the ‘compression’ signs are regarded as the most important US abnormalities for GCA. The inter-rater and intra-rater agreement of the new OMERACT definitions for US lesions in GCA was excellent.
Erfassung der Körperzusammensetzung
Schmidt, Steffen , Krell-Rösch, Janina

Mayo Clinic

B&G Bewegungstherapie und Gesundheitssport | May 15, 2018 | Volume: 34 | Issue: 02 | Pages: 82-87

10.1055/a-0569-6669 Get It

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli
Schmidt-Malan, Suzannah M., Mishra, Avisya J., Mushtaq, Ammara , Brinkman, Cassandra L., Patel, Robin , Patel, Robin

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 15, 2018 | Volume: 62 | Issue: 8 | Pages: No page available

10.1128/aac.00533-18 | PMID 29760145 Get It

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam–β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli.
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Sciver, Robert E. Van , Lee, Michael , Lafever, Alex, Svyatova, Elizaveta , Kanda, Kevin, Collier, Amber L. , Reesema, LL Siewertsz van, Tang-Tan, Angela M., Zheleva, Vasilena, Bwayi, Monicah, Bian, Minglei, Schmidt, Rebecca L., Matrisian, Lynn M. , Petersen, Gloria M. , Van Sciver, Robert E , Matrisian, Lynn M , Lee, Caroline Guat Lay , Tang, Amy

Mayo Clinic

Cancers | May 15, 2018 | Volume: 10 | Issue: 5 | Pages: 142

10.3390/cancers10050142 | PMID 29757973 Get It

Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.